Recent advances in anti-infective drug discovery最新文献

{"title":"<i>In vitro</i> and <i>In silico</i> Assessment of the Antiviral Potential of Green Tea, Green Coffee, Pomegranate Peel, and Orange Peel.","authors":"Noha Sabry Mokhtar, Sabha Mahmoud El-Sabagh, Aly Fahmy Mohamed, Hanaa Mohamed Salama, Mohammed Yosri Afifi, Basma Hamdy Amin","doi":"10.2174/0127724344313315240809093115","DOIUrl":"https://doi.org/10.2174/0127724344313315240809093115","url":null,"abstract":"<p><strong>Background: </strong>Viral infections pose a great burden for humankind and many viruses have no effective treatments. Hepatitis A Virus (HAV) and Coxsackie-B4 (Cox- B4) are common viruses having many drawbacks. Using plant extracts as antiviral agents is a globally applied approach due to its efficacy and minimal adverse effects.</p><p><strong>Objective: </strong>This study aimed to test the antiviral action of the green coffee extract against HAV and Cox-B4 viruses, assess the possible mechanisms regulating this role, and apply molecular docking to evaluate the connection between bioactive compounds in the green coffee extract and viral proteins and receptors.</p><p><strong>Methods: </strong>The antiviral effect of four plant extracts, including green tea, green coffee, pomegranate peel, and orange peel on HAV and Cox-B4 viruses has been screened in this study. The most promising results have been obtained using an inverted microscope and electron microscopy. Gas Chromatography-Mass Spectrometry (GC-MS) has been used to detect various compounds in the green coffee extract. Gene expression of MxA has been examined in different groups of treatments. Oxidative enzymes, including Glutathione (GSH), Superoxide Dismutase (SOD), and Malondialdehyde (MDA) were tested in infected Vero cells (African green monkey kidney cells) and upon using green coffee. In silico studies were performed using molecular docking software.</p><p><strong>Results: </strong>Green coffee has been found to have an antiviral impact on HAV and Cox-B4 with IC₅₀= 8.8±0.6 and 14.5±0.8 μg/ml, respectively, visualizing and confirming the results using both Transmission Electron Microscope (TEM) and inverted microscope. The green coffee extract has been found to regulate oxidative enzymes, including SOD, GSH, and MDA, to normal concentrations as well as MxA gene expression to regular levels. Linoleic acid and arachidic acid have been found to be the most common molecules in green coffee extract, interacting with the tested viruses.</p><p><strong>Conclusion: </strong>Green coffee methanolic extract has been found to have an efficient antiviral impact on HAV and Cox-B4 viruses, as validated by <i>in vivo</i> investigations.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"20 2","pages":"112-127"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiviral Bioactive Compounds: Their Activities and Underlying Mechanisms Against Human Viral Infections.","authors":"Somnath Ghosh, Koushik Jana, Pijus Parua, Arnab Seth, Amlan Bishal, Biplab Debnath, Saroj Kumar Rout, Jitu Halder, Vineet Kumar Rai, Priyanka Dash, Chandan Das, Biswakanth Kar, Goutam Ghosh, Goutam Rath","doi":"10.2174/0127724344376918250328054623","DOIUrl":"10.2174/0127724344376918250328054623","url":null,"abstract":"<p><strong>Background: </strong>Viral infections continue to be a major global health issue, causing over five million fatalities and millions of hospitalizations every year. Existing vaccines and commonly used antiviral drugs often exhibit significant side effects and limited efficacy. In contrast, recent studies have shown that plant extracts and their bioactive compounds possess considerable antiviral activity, along with a favourable safety profile for long-term use. These findings have spurred increased interest in the discovery and development of novel plant-derived antiviral agents.</p><p><strong>Aim: </strong>This review emphasizes the significance of plant-derived antiviral compounds and their corresponding therapeutic targets. It provides a comprehensive overview of recent research on phytochemicals with potential antiviral activity against a wide range of viruses. By consolidating current findings, this review serves as a unified and up-to-date resource on contemporary plant-based antiviral bioactive compounds used in the treatment of human viral infections.</p><p><strong>Methods: </strong>The antiviral efficacy of selected phytoactive compounds was analysed through detailed molecular mechanism studies, supported by in vitro and/or in vivo experimental models. Key herbs were reviewed for their active compounds and antiviral activities against specific viruses like influenza, HIV, HBV, HCV, HSV SARS-CoV-2, and measles. The study also analyzed the results, comparing their mechanisms of action, such as immune modulation, inhibition of viral entry, or interference with replication, while also discussing limitations and gaps in current research.</p><p><strong>Results: </strong>Evidence from the literature suggests that the notable selectivity of herbal bioactive compounds toward viral target proteins may underlie their antiviral activity. Additionally, findings from <i>in silico, in vitro</i>, and <i>in vivo</i> studies indicate that these compounds exert their effects by binding to specific host cell components, thereby protecting the host from viral infection. This review identifies and summarizes over 150 plant-derived antiviral bioactive compounds, along with their respective mechanisms of action, that have demonstrated efficacy against various selected viruses.</p><p><strong>Conclusion: </strong>Plant-derived compounds, such as alkaloids, flavonoids, phenolics, terpenoids, and coumarins, exhibit significant antiviral potential. Given the limited number of approved antiviral drugs, cellular and molecular evidence supports herbal bioactives as promising alternatives for developing effective antiviral therapies, offering a natural and safer approach to combating viral infections.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":"267-325"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Microbiome Research: Implications for Infectious Disease Management and Treatment.","authors":"Anas Islam","doi":"10.2174/0127724344384934250624040634","DOIUrl":"10.2174/0127724344384934250624040634","url":null,"abstract":"<p><strong>Introduction: </strong>The human microbiome plays a pivotal role in health and disease, with microbial imbalances (dysbiosis) increasingly linked to heightened susceptibility to infections and exacerbated disease severity. This review explores how the microbiome confers protection through mechanisms, such as colonization resistance, immune modulation, and antimicrobial metabolite production, while also examining its potential as a predictive tool for infection risk and outcomes, as exemplified in COVID-19.</p><p><strong>Methods: </strong>This article synthesizes current literature on microbiome dynamics, leveraging advances in high-throughput sequencing, bioinformatics, and machine learning to analyze microbial profiles and identify biomarkers. It evaluates microbiome-based therapeutic strategies, including probiotics, prebiotics, and engineered microbes, and assesses challenges in translating these approaches into clinical practice.</p><p><strong>Results: </strong>Microbiome profiles demonstrate prognostic value in predicting infection risk and severity, supported by enhanced analytical tools that enable precise biomarker discovery for diagnostics and personalized medicine. Therapeutic interventions show promise in restoring microbial balance and combating infections, though clinical adoption is hindered by variability, regulatory hurdles, and the need for standardized methodologies.</p><p><strong>Conclusion: </strong>Integrating microbiome insights into clinical practice requires rigorous clinical trials, standardized protocols, and resolution of ethical and regulatory challenges. Future research should focus on elucidating microbiome-host-pathogen interactions and developing targeted interventions, and advanced computational models are critical to unlocking the full potential of microbiome-based diagnostics and therapeutics for infectious disease management.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":"251-266"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aetiology of Fever of Unknown Origin in Two Middle Delta Egyptian Tertiary Health Care Facilities.","authors":"Rawnaa Eldeeb, Eslam Habba, Sherief Abd-Elsalam, Ferial El-Kalla","doi":"10.2174/0127724344345490250605065612","DOIUrl":"10.2174/0127724344345490250605065612","url":null,"abstract":"<p><strong>Introduction: </strong>Fever of Unknown Origin (FUO) was first defined in 1961 as a temperature greater than 38.3°C on several occasions, lasting for more than 3 weeks, or failure to reach a diagnosis despite one week of inpatient investigation. The time frame has recently been revised to include patients whose illness remains undiagnosed after either a minimum of three outpatient visits or three days of hospitalization. The purpose of this study was to describe the etiology, frequency, and pattern of different causes, particularly infectious causes, and to determine the relative incidence of various causes of FUO in the mid-Delta area of Egypt.</p><p><strong>Methods: </strong>This retrospective cohort study included all FUO cases registered in the file system over a seven-year period from 2015 to 2022 at Mahala-Kubra Fever Hospital, as well as all admitted FUO cases at the Tropical Medicine and Infectious Diseases Department of Tanta University during 2021 and 2022.</p><p><strong>Results: </strong>A total of 383 FUO cases were included in the study. Among these, the leading causes of FUO were infections (n = 334, 87.2%), followed by neoplasms (n = 26, 6.8%). Autoimmune and miscellaneous causes ranked third (n = 9, 2.3%), and undiagnosed cases were the least common (n = 5, 1.3%). The two most common infectious causes in this study were urinary tract infection (n = 136, 40.7%) and brucellosis (n = 115, 34.4%). Typhoid fever (n = 29, 8.7%), pneumonia (n = 15, 4.2%), and abscesses (n = 10, 3.0%) were also frequent causes of FUO. Hematological malignancies were the most common malignant causes of FUO, with lymphoma being the most prevalent (n = 10, 38.5%), followed by leukemia (n = 8, 30.8%).</p><p><strong>Conclusion: </strong>Fever (pyrexia) of unknown origin remains one of the most challenging complexities in medical diagnosis. Infections, particularly Urinary Tract Infections (UTIs) and brucellosis, are the primary causes of FUO in this study. It is also important to recognize that hematological malignancies are a significant cause of FUO.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":"338-349"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial Resistance Patterns and the Role of Antibiotic Stewardship in a Secondary Care Hospital.","authors":"Aakash Ramanisankar, Nirenjen Shanmugasundaram, Maheswari Paramasivam, E M Neena Priyamalar, Aswin Pratap Sundararajan, Deepak Raj Sivakumar, Dharshne Petchiammal Thirupathi","doi":"10.2174/0127724344369266250310084603","DOIUrl":"10.2174/0127724344369266250310084603","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial Resistance (AMR) has emerged as a critical global health challenge, with bacteria, viruses, fungi, and parasites developing the capacity to survive antimicrobial treatments. This resistance, largely driven by increased antibiotic usage, threatens public health by diminishing the effectiveness of current infection management strategies.</p><p><strong>Aim and objectives: </strong>This study aims to evaluate the antimicrobial resistance patterns of prevalent pathogens in a secondary care hospital, highlighting the essential role of clinical pharmacists in addressing AMR through the implementation of Antibiotic Stewardship Programs (ASPs) to promote responsible antibiotic use.</p><p><strong>Methodology: </strong>This prospective study analyzed 80 positive microbial culture reports from six months. Ethical approval was granted by the Institutional Ethical Committee (Ref: ECR/288/Indt/TN/2018/RR-21/001, dated April 6, 2023). Inclusion criteria covered adults (≥18 years) with confirmed infections across various sites, including bloodstream, urinary, respiratory, and soft tissue. Exclusion criteria eliminated reports with no pathogen growth. Data were analyzed using SPSS software version 26.0, with statistical measures applied to assess resistance patterns and correlations across infection types.</p><p><strong>Results: </strong>Of the 80 positive cultures, Escherichia coli 35.0%) was most frequently isolated, followed by Klebsiella pneumoniae (12.5%), Pseudomonas aeruginosa (8.8%), Proteus mirabilis (8.8%), and Klebsiella oxytoca (7.5%). The isolated pathogens displayed high resistance to ampicillin (82.5%), cefixime (80.0%), ceftriaxone (78.8%), and ceftazidime (71.3%), with a strong sensitivity to amikacin (86.3%) and meropenem (70.0%).</p><p><strong>Conclusion: </strong>The rise of third-generation cephalosporin-resistant pathogens signals an urgent need for sustained AMR monitoring and robust ASPs in healthcare settings, particularly in developing regions. The study underscores the importance of rational antibiotic use and continuous AMR surveillance to curb resistant infections and protect public health.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":"203-222"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In silico</i> Screening of Plant Compounds to Inhibit MexB Efflux Protein for the Enhancement of Meropenem Resistance against <i>Pseudomonas aeruginosa</i> MDR Infections.","authors":"Praveena Nanjan, B Vanitha Bose","doi":"10.2174/0127724344343717250404114236","DOIUrl":"https://doi.org/10.2174/0127724344343717250404114236","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;&lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; is a common cause of healthcare-associated infections such as Pneumonia, Bloodstream, Urinary tract, and Surgical site infections this bacterium is also reported to cause infections in cancerous cells. It is one of the most considered opportunistic human pathogens, especially in immunocompromised patients, and one of the top five pathogens of nosocomial diseases worldwide. Some &lt;i&gt;P. aeruginosa&lt;/i&gt; are becoming more resistant to even antibiotics of last resort, including beta-lactams, fluoroquinolones, tetracycline, chloramphenicol, macrolides, and aminoglycosides, and are described as multidrug-resistant. Multiple lines of evidence suggest that the chief mechanism for &lt;i&gt;P. aeruginosa&lt;/i&gt; is resistance to antibiotics regulated by the efflux pumps. Antibiotic efflux pumps are membrane proteins that actively remove antibiotics from the bacterial cell, lowering on-target antibiotic concentrations to sub-toxic levels. The MexAB-OprM system is one of the largest multi-drug resistant clinically relevant efflux pumps with high expression levels in P. aeruginosa. Inhibition of these MDR efflux pumps can restore the activity of antimicrobial agents that are substrates for this protein. We performed molecular modelling studies in this study to discover novel Mex B efflux pump inhibitors. We evaluated the MIC of α-Bisabolol and Meropenem combination against Meropenem-resistant Pseudomonas Aeruginosa strains. This research opened up the possibility of using this plant compound α-Bisabolol and resistance drug Meropenem combination in the development of medicines for human consumption, possibly for the treatment of Hospital-Acquired Pneumonia, and multidrug- resisting infection caused by &lt;i&gt;P. Aeruginosa&lt;/i&gt; including wound and urinary infections which have been reported important HAI carbapenem class multidrug infections caused by the bacteria.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The present study investigates the interactions of plant secondary metabolites tables on Mex B efflux protein. It identifies lead molecules for developing adjuvants against efflux-mediated multidrug resistance in P. aeruginosa infections, enhances antibiotic activity against MDR pathogens, and evaluates the MIC value of the test plant compound (Bisabolol) and the resistant antibiotic (Meropenem).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among plant compounds, α-Bisabolol, myricetin, capsaicin, equenin, aloe-emodin, terpinene, fisetin, taxifolin, catechin, and galangin showed G-Scorehigher than -7 kcal/mol, and interact with active amino acids Mex B efflux protein which may affect the efflux transport of drug and enhance the antibiotic activity against MDR infection. According to docking experiments, α-bisabolol has a higher affinity energy to the MexB protein than Meropenem. Furthermore, α-bisabolol binds to the MexB binding site hydrophobic trap region of MexB, which may cause a conformational change in the transporter's pumping proc","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"20 3","pages":"223-250"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145643697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering Plasmodium Condensin Core Subunits of Structural Maintenance of Chromosomes 2 (SMC2) as a Putative Drug Target for Antimalarial Drug.","authors":"Uma Chauhan, Manali Datta, Sanket Kaushik, Vinay Sharma, Sakshi Piplani, Ravi Ranjan Kumar Niraj","doi":"10.2174/0127724344313755241021055002","DOIUrl":"https://doi.org/10.2174/0127724344313755241021055002","url":null,"abstract":"<p><strong>Background: </strong>The structural maintenance of chromosomes (SMC) proteins plays a noteworthy role in chromosome dynamics. Several recent studies reported that the condensin core subunits of structural maintenance of chromosomes 2 (SMC2) play important roles in the atypical mitosis of the Plasmodium life cycle and may perform different functions during different proliferative stages. For eukaryotes, the structural maintenance of chromosomes (SMC) proteins are divided into six subunits and form three heterodimers of structural maintenance of chromosomes (SMC1/3) cohesion complex, structural maintenance of chromosomes (SMC2/4) condensin complex, and structural maintenance of chromosomes (SMC5/6) complex for chromosome cohesion, condensation, and DNA damage repair, respectively.</p><p><strong>Objective: </strong>The objective of this study was to investigate the structural maintenance of chromosomes 2 (SMC2) protein of <i>P. falciparum</i> as a putative drug target of malariacausing <i>Plasmodium falciparum</i>.</p><p><strong>Methods: </strong>In this study, we investigated the structural maintenance of chromosomes 2 (SMC2) protein of <i>P. falciparum</i> as a putative drug target of malaria-causing <i>P. falciparum</i> by using <i>in-silico</i> approaches like Homology modeling, <i>in-silico</i> evaluation of the modeled structure, molecular docking study to investigate the interaction of receptor-ligand, and molecular dynamic simulation study with MM calculation.</p><p><strong>Results: </strong>We reported the structural maintenance of chromosomes 2 (SMC2) protein of <i>P. falciparum</i> as a potent drug target that can pave the way for novel drug discovery to mitigate malaria.</p><p><strong>Conclusion: </strong><i>In-silico</i>-based studies play a significant role in understanding any protein for potential drug development.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"20 2","pages":"128-138"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combating Amoebic Meningoencephalitis in Kerala and other Indian States.","authors":"Sanjesh Kumar, Mansi Singh","doi":"10.2174/0127724344356382241024101557","DOIUrl":"https://doi.org/10.2174/0127724344356382241024101557","url":null,"abstract":"","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"20 1","pages":"2-4"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bedaquiline Delivery Innovations: A Review on Advancing MDR-TB Treatment Strategies.","authors":"Asad Ahmad, Juber Akhtar, Mohammad Ahmad, Badruddeen, Mohammad Irfan Khan, Aditya Singh, Anas Islam","doi":"10.2174/0127724344318310241018113206","DOIUrl":"https://doi.org/10.2174/0127724344318310241018113206","url":null,"abstract":"<p><p>Multidrug-resistant tuberculosis (MDR-TB) poses a persistent challenge to global health, necessitating continuous efforts to enhance treatment efficacy. Bedaquiline, a cornerstone in MDR-TB management, presents biopharmaceutical challenges that impact its therapeutic potential. This review provides a comprehensive analysis of recent innovations in drug delivery strategies designed to optimize Bedaquiline's efficacy and improve MDR-TB treatment outcomes. Through a systematic examination of various delivery systems, including nanotechnology and formulation advancements, we explore their potential in addressing drug solubility and bioavailability challenges. Emphasizing the integration of Quality by Design (QbD) principles, this review aims to present a cohesive overview of evolving Bedaquiline delivery innovations, providing valuable insights for researchers and healthcare practitioners working towards advancing MDR-TB treatment strategies.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"20 2","pages":"92-111"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Therapeutic Approaches Emerging in the Field of Onychomycosis.","authors":"Gurisha Garg, Raj Kamal, Sonakshi Garg, Preeti Patel, Balak Das Kurmi","doi":"10.2174/0127724344335834250112164400","DOIUrl":"10.2174/0127724344335834250112164400","url":null,"abstract":"<p><p>Onychomycosis is regarded as one of the most common and least concerned fungal problems. Although various treatment approaches have been well-established, still treatment strategies suffer from certain drawbacks, so there is a need to discuss novel therapies that could ultimately eliminate all the conventional barriers. It is a nail infection that begins in the toenail and spreads, causing significant negative impacts on patients' quality of life. The purpose of this work was to highlight the limitations of conventional treatments and shed light on novel therapies for managing onychomycosis. A comprehensive review on existing topical and systemic therapies was conducted, with a focus on their drawbacks, such as recurrence and lower efficacy. This review aimed to explore the increasing prevalence of onychomycosis, which poses a serious health issue; however, the advent of nanobased drug delivery systems offers hope for more effective management of this prevalent disease. These systems could potentially overcome the limitations of conventional treatments, thereby improving patient outcomes.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":"157-167"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}